Within-trial evaluation of medical resources, costs, and quality of life among patients with type 2 diabetes participating in the exenatide study of cardiovascular event lowering (... by Reed, S, Li, Y, Dakin, H, Becker, F, Leal, J, Gustavson, S, Kartman, B, Wittbrodt, E, Mentz, R, Pagidipati, N, Bethel, M, Gray, A, Holman, R, Hernandez, A

Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL by Reed, S, Li, Y, Dakin, H, Becker, F, Leal, J, Gustavson, S, Kartman, B, Wittbrodt, E, Mentz, R, Pagidipati, N, Bethel, M, Gray, A, Holman, R, Hernandez, A

EXSCEL—once-weekly exenatide reduces medical resource utilization in patients with type 2 diabetes mellitus by Reed, S, Li, Y, Dakin, H, Becker, F, Leal, J, Gustavson, S, Kartman, B, Wittbrodt, E, Mentz, R, Pagidipati, N, Bethel, M, Gray, A, Holman, R, Hernandez, A

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). by Mentz, R, Bethel, M, Gustavson, S, Thompson, V, Pagidipati, N, Buse, J, Chan, J, Iqbal, N, Maggioni, A, Marso, S, Ohman, P, Poulter, N, Ramachandran, A, Zinman, B, Hernandez, A, Holman, R

Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial by Holman, R, Bethel, M, George, J, Sourij, H, Doran, Z, Keenan, J, Khurmi, N, Mentz, R, Oulhaj, A, Buse, J, Chan, J, Iqbal, N, Kundu, S, Maggioni, A, Marso, S, Öhman, P, Pencina, M, Poulter, N, Porter, L, Ramachandran, A, Zinman, B, Hernandez, A